(News Bulletin 247)- AstraZeneca reports that Lynparza (olaparib) + abiraterone and prednisone or Lynparza + prednisolone regimens have been approved in the United States for the treatment of adult patients with metastatic castration-resistant prostate cancer ( mCRPC) with BRCA mutation (BRCAm).
This approval is based on a Phase III trial which showed that Lynparza + abiraterone resulted in ‘very clinically meaningful improvements’ in both radiographic progression-free survival (rPFS) and overall survival compared to abiraterone alone.
‘The results of this trial showed that the Lynparza combination demonstrated remarkable clinically significant benefit that should quickly be considered the gold standard treatment for patients with metastatic castration-resistant prostate cancer with a BRCA mutation’ , commented Andrew Armstrong, of the Duke Cancer Institute, Durham, North Carolina.
Prostate cancer is the second most common cancer in men and despite an increase in the number of treatments available for patients with mCRPC, five-year survival remains low.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
